October 3, 2024 07:29 AM EDTUpdated 12:11 PM
Pharma

Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run

Ayisha Sharma

News Reporter

Eli Lil­ly’s block­buster GLP-1 drug tirzepatide is fi­nal­ly back on track in the US af­ter two years of in­ter­mit­tent short­ages dri­ven by high de­mand, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

A service from the Financial Times